Skip to Main content Skip to Navigation
Master Thesis

Place de l'immunothérapie dans le traitement des cancers buccaux

Abstract : Head and neck cancers are ranked 7th most common cancer in the world, with 890,000 new cases and 450,000 deaths in 2018. Often diagnosed at an advanced stage, the prognosis and survival remain poor: 50 % of patients will present with locoregional recurrence and 20% will have metastases. Faced with this observation, new therapeutic approaches are necessary. The ability of the immune system to recognize and eradicate tumor cells has been a hypothesis raised since the beginning of the 20th century. In 1909, Paul Ehrlich hypothesized that immune defenses prevent the transformation of neoplastic cells into tumors. Immunotherapy then takes its place in the therapeutic arsenal. Instead of attacking tumor cells like chemotherapy and radiation therapy do, the idea is to work directly on a patient's immune system to make it able to destroy cancer cells. PD-1 and PD-L1 inhibitors as well as CTLA-4 have emerged as valid options for patients with squamous cell carcinoma of the head and neck. This study highlights the value of these new therapies against cancer cells in the oral cavity. The synthesis of knowledge promotes the evolution of practices and the implementation of these new treatments by health professionals.
Complete list of metadata
Contributor : Odonto UB - Connect in order to contact the contributor
Submitted on : Friday, December 10, 2021 - 9:59:22 AM
Last modification on : Tuesday, December 14, 2021 - 3:57:00 AM
Long-term archiving on: : Friday, March 11, 2022 - 6:28:20 PM


Files produced by the author(s)


  • HAL Id : dumas-03474155, version 1



Maïté Boussiron. Place de l'immunothérapie dans le traitement des cancers buccaux. Sciences du Vivant [q-bio]. 2021. ⟨dumas-03474155⟩



Record views


Files downloads